Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX December Winners: Santa didn’t rally but at least these 50 stocks went okay
Health & Biotech
Health Check: Percheron board addresses shareholders after failed phase 2b trial
Health & Biotech
Health Check: Local biotech starred in 2024, but the rising tide did not lift all boats
Health & Biotech
Scott Power: Which stock fell off its perch on poor trial results this week?
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
News
ASX Lunch Wrap: ASX higher ahead of Fed; MinRes completes $780m gas deal with Rinehart
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Health Check: Clinical trials don’t sleigh down for the silly season
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Scott Power: Which small medtech lifted 70pc this week after US contract win?
Health & Biotech
Health Check: No sign of frayed nerves as Orthocell girds for US approval
Health & Biotech
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
Health & Biotech
Five ASX healthcare companies poised for game-changing catalysts
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Dr Boreham’s Crucible: Does this biotech have the horsepower to become ‘the next Neuren’?
Health & Biotech
Health Check: ‘Cannabis corner’ in the green with record revenues and favourable deals
Health & Biotech
